Schrödinger Q4 2023 Investor Presentation

Schrödinger's Q4 FY23 investor update covering the company's progress in drug development software and consulting solutions. The presentation discusses the integration of the recently acquired Immunetrics business and market opportunities in pharmaceutical R&D optimization.